4D Molecular Therapeutics (FDMT) Accounts Payables: 2019-2025
Historic Accounts Payables for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $6.9 million.
- 4D Molecular Therapeutics' Accounts Payables rose 134.71% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 134.71%. This contributed to the annual value of $4.4 million for FY2024, which is 24.78% up from last year.
- Per 4D Molecular Therapeutics' latest filing, its Accounts Payables stood at $6.9 million for Q3 2025, which was down 21.11% from $8.7 million recorded in Q2 2025.
- 4D Molecular Therapeutics' Accounts Payables' 5-year high stood at $8.7 million during Q2 2025, with a 5-year trough of $1.3 million in Q1 2021.
- In the last 3 years, 4D Molecular Therapeutics' Accounts Payables had a median value of $4.2 million in 2025 and averaged $4.4 million.
- As far as peak fluctuations go, 4D Molecular Therapeutics' Accounts Payables tumbled by 60.14% in 2022, and later skyrocketed by 218.45% in 2023.
- Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Accounts Payables stood at $4.8 million in 2021, then slumped by 30.27% to $3.3 million in 2022, then increased by 5.81% to $3.5 million in 2023, then increased by 24.78% to $4.4 million in 2024, then soared by 134.71% to $6.9 million in 2025.
- Its last three reported values are $6.9 million in Q3 2025, $8.7 million for Q2 2025, and $4.2 million during Q1 2025.